These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19933802)

  • 41. [Conjugative transfer of glycopeptide and macrolide resistant genes among Enterococci and from Enterococcus faecalis to Staphylococcus aureus].
    Młynarczyk A; Młynarczyk G; Łuczak M
    Med Dosw Mikrobiol; 2002; 54(1):21-8. PubMed ID: 12185680
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthetic Biology Facilitates Semisynthetic Development of Type V Glycopeptide Antibiotics Targeting Vancomycin-Resistant
    Koteva K; Xu M; Wang W; Fiebig-Comyn AA; Cook MA; Coombes BK; Wright GD
    J Med Chem; 2023 Jul; 66(13):9006-9022. PubMed ID: 37315221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci.
    Franchi D; Climo MW; Wong AH; Edmond MB; Wenzel RP
    Clin Infect Dis; 1999 Dec; 29(6):1566-8. PubMed ID: 10585815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Studies for the development of novel anti-MRSA/VRE drugs].
    Hashizume H
    Yakugaku Zasshi; 2012; 132(1):59-67. PubMed ID: 22214581
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hidden Mode of Action of Glycopeptide Antibiotics: Inhibition of Wall Teichoic Acid Biosynthesis.
    Singh M; Chang J; Coffman L; Kim SJ
    J Phys Chem B; 2017 Apr; 121(16):3925-3932. PubMed ID: 28368603
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
    Mercier RC; Stumpo C; Rybak MJ
    J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
    [TBL] [Abstract][Full Text] [Related]  

  • 47. VanA-type Staphylococcus aureus strain VRSA-7 is partially dependent on vancomycin for growth.
    Moubareck C; Meziane-Cherif D; Courvalin P; Périchon B
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3657-63. PubMed ID: 19528271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of the peptidoglycan of vancomycin-susceptible Enterococcus faecium.
    Patti GJ; Kim SJ; Schaefer J
    Biochemistry; 2008 Aug; 47(32):8378-85. PubMed ID: 18642854
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin.
    Hill CM; Krause KM; Lewis SR; Blais J; Benton BM; Mammen M; Humphrey PP; Kinana A; Janc JW
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2814-8. PubMed ID: 20404117
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of a novel series of semisynthetic vancomycin derivatives effective against vancomycin-resistant bacteria.
    Nakama Y; Yoshida O; Yoda M; Araki K; Sawada Y; Nakamura J; Xu S; Miura K; Maki H; Arimoto H
    J Med Chem; 2010 Mar; 53(6):2528-33. PubMed ID: 20180534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glycopeptide antibiotics and their novel semi-synthetic derivatives.
    Jeya M; Moon HJ; Lee KM; Kim IW; Lee JK
    Curr Pharm Biotechnol; 2011 Aug; 12(8):1194-204. PubMed ID: 21470154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides.
    Tevyashova AN; Bychkova EN; Korolev AM; Isakova EB; Mirchink EP; Osterman IA; Erdei R; Szücs Z; Batta G
    Bioorg Med Chem Lett; 2019 Jan; 29(2):276-280. PubMed ID: 30473176
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of Staphylococcus aureus Cell Wall Biosynthesis by Desleucyl-Oritavancin: a Quantitative Peptidoglycan Composition Analysis by Mass Spectrometry.
    Chang JD; Foster EE; Thadani AN; Ramirez AJ; Kim SJ
    J Bacteriol; 2017 Aug; 199(15):. PubMed ID: 28507244
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC; Ribou G; Masquelier B
    Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of transglycosylation involved in bacterial peptidoglycan synthesis.
    Goldman RC; Gange D
    Curr Med Chem; 2000 Aug; 7(8):801-20. PubMed ID: 10828288
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Model for antibiotic optimization via neoglycosylation: synthesis of liponeoglycopeptides active against VRE.
    Griffith BR; Krepel C; Fu X; Blanchard S; Ahmed A; Edmiston CE; Thorson JS
    J Am Chem Soc; 2007 Jul; 129(26):8150-5. PubMed ID: 17564440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Glycopeptide antibiotics: from conventional molecules to new derivatives.
    Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
    Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acquired and intrinsic glycopeptide resistance in enterococci.
    Gholizadeh Y; Courvalin P
    Int J Antimicrob Agents; 2000 Nov; 16 Suppl 1():S11-7. PubMed ID: 11137403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fluorescence assay to predict activity of the glycopeptide antibiotics.
    Vimberg V; Gazak R; Szűcs Z; Borbás A; Herczegh P; Cavanagh JP; Zieglerova L; Závora J; Adámková V; Balikova Novotna G
    J Antibiot (Tokyo); 2019 Feb; 72(2):114-117. PubMed ID: 30504918
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
    Belley A; McKay GA; Arhin FF; Sarmiento I; Beaulieu S; Fadhil I; Parr TR; Moeck G
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5369-71. PubMed ID: 20876372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.